Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2a Randomized, Double-blind, Placebo-controlled, Multicenter Study To Evaluate The Efficacy And Safety Profile Of Pf-06651600 And Pf-06700841 In Subjects With Moderate To Severe Alopecia Areata With A Single-blind Extension Period And A Cross-over Open Label Extension Period

Next Previous
X
Search
Trial Profile

A Phase 2a Randomized, Double-blind, Placebo-controlled, Multicenter Study To Evaluate The Efficacy And Safety Profile Of Pf-06651600 And Pf-06700841 In Subjects With Moderate To Severe Alopecia Areata With A Single-blind Extension Period And A Cross-over Open Label Extension Period

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 13 Dec 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Brepocitinib (Primary) ; Ritlecitinib (Primary)
  • Indications Alopecia areata
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Pfizer

    • Most Recent Events

    • 01 Dec 2022 Results (from 5 clinical trials; NCT02310750 NCT03236493 NCT03656952 NCT02969018 NCT02974868 ) assessing Population Pharmacokinetics of Oral Brepocitinib in Healthy Volunteers and Patients published in the Clinical Pharmacology in Drug Development
    • 14 Nov 2022 Results (A cross study dose response analysis of five Phase 2 studies N=218, NCT03963401; N=212, NCT02969018; N=167, NCT02958865; N=94, NCT02974868;N=100 NCT04092452 ) assessing Pharmacologic and Clinical Rationale Brepocitinib for the Treatment of Dermatomyositis presented at the ACR Convergence 2022
    • 01 Apr 2022 Results assessing Report scores from the Alopecia Areata Symptom Impact Scale (AASIS; a patient-reported outcome tool) and explore the relationships of those scores with clinician-assessed Severity of Alopecia Tool (SALT) scores at baseline and week 24, published in the Journal of the European Academy of Dermatology and Venereology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top